DNA nanostructures are emerging as a versatile platform for controlled drug delivery as a result of recent progress in production yield and strategies to obtain prolonged stability in biological environments. The construction of nanostructures from this unique biomaterial provides unparalleled control over structural and functional parameters. Recent applications of DNA origami-based nanocarriers for therapeutic drug delivery in preclinical phases highlight them as promising alternatives to conventional nanomaterials, as they benefit from the inherent favorable properties of DNA including biocompatibility and precise spatial addressability. By incorporating targeting aptamers and responsive properties into the nanocarrier design, more selective DNA origami-based nanocarriers are successfully prepared. On the other hand, current systems remain poorly understood in terms of biodistribution, final fate, and controlled drug release. As such, advances are needed to translate this material platform in its full potential for therapeutic applications.

由于生产产量和在生物环境中获得长期稳定性的策略的最新进展，DNA纳米结构正逐渐成为控制药物输送的通用平台。由这种独特的生物材料构造的纳米结构为结构和功能参数提供了无与伦比的控制。基于DNA折纸的纳米载体在临床前阶段用于治疗性药物输送的最新应用突显出它们是常规纳米材料的有希望的替代品，因为它们受益于DNA固有的良好特性，包括生物相容性和精确的空间寻址能力。通过将靶向适体和响应特性纳入纳米载体设计，成功制备了更具选择性的基于折纸的DNA纳米载体。另一方面，目前的系统在生物分布，最终命运和药物控制释放方面仍然知之甚少。因此，需要进步以充分利用这种材料平台的治疗应用潜力。